SCHEMBL2007808

SCHEMBL2007808

NC(=O)c1ccc2oncc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.46
CHRNA7 P36544 1/20 0.45
PLAU P00749 4/20 0.41
TSHR P16473 1/20 0.40
APP P05067 2/20 0.39
AR P10275 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PARP1 P09874 1/20 0.39
NNMT P40261 1/20 0.39
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR2C P28335 1/20 0.39
SYK P43405 2/20 0.38
KDM4E B2RXH2 1/20 0.38
BRD4 O60885 1/20 0.38
ALDH1A1 P00352 1/20 0.38
BRPF1 P55201 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MKNK1 Q9BUB5 2/20 0.37
MKNK2 Q9HBH9 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31605591 1.00 LCK (0.46) LCKCHRNA7PLAUTSHRAPP
SCHEMBL30029315 0.86 LCK (0.46) LCKPLAUTSHRAPPAR
SCHEMBL2010481 0.86 LCK (0.46) LCKPLAUTSHRAPPAR
SCHEMBL15660345 0.84 CHRNA7 (0.49) CHRNA7TSHRSMN1; SMN2KDM4EALDH1A1
SCHEMBL2007804 0.82 CHRNA7 (0.45) CHRNA7PLAUSYK
SCHEMBL31605579 0.82 CHRNA7 (0.45) CHRNA7TSHRSMN1; SMN2SYKALDH1A1
SCHEMBL31605605 0.78 RAB9A (0.48) LCKCHRNA7SMN1; SMN2KDM4EALDH1A1
SCHEMBL28421020 0.75 MEN1 (0.46) CHRNA7SMN1; SMN2SYK
SCHEMBL28348940 0.73 CHRNA7 (0.42) CHRNA7SMN1; SMN2ALDH1A1
SCHEMBL29652505 0.72 NNMT (0.41) PARP1NNMTSYKMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP claimed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO claimed
CN-117903110-A HBV inhibitors and uses thereof 西安新通药物研究股份有限公司 2024-04-19 CN disclosed
CN-114901639-B HBV inhibitors and uses thereof 西安新通药物研究股份有限公司 2023-11-24 CN disclosed
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 LCK 584/4885CHRNA7 110/4885PLAU 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.